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10.The etiology of chest pain in hypertrophic cardiomyopathy (HC) is diverse and includes cor-
onary artery disease (CAD) as well as HC-specific causes. Myocardial bridging (MB) has
been associated with HC, chest pain, and accelerated atherosclerosis. We compared HC
patients with age-, gender- and CAD pre-test probability-matched outpatients presenting
with chest pain to investigate differences in the presence of MB and CAD using coronary
computed tomography angiography (CCTA). We studied 84 HC patients who underwent
CCTA and compared these with 168 matched controls (age 54 § 11 years, 70% men, pre-
test probability 12% [5% to 32%]). MB, calcium score, plaque morphology and presence
and extent of CAD were assessed for each patient. Linear mixed models were used to assess
differences between cases and controls. MB was more often seen in HC patients (50% vs
25%, p <0.001). Calcium score and the presence of obstructive CAD were similar in both
groups (9 [0 to 225] vs 4 [0 to 82] and 18% vs 19%; p = 0.22 and p = 0.82). In the HC group,
MB was associated with pathogenic DNA variants (p = 0.04), but not with the presence of
chest pain (74% vs 76%, p = 0.8), nor with worse outcome (log-rank p = 0.30). In conclusion,
the prevalence and extent of CAD was equal among patients with and without HC, demon-
strating that pre-test risk prediction using the CAD Consortium clinical risk score performs
well in HC patients. MB was twice as prevalent in the HC group compared with matched
controls, but was not associated with chest pain or decreased event-free survival in these
patients. © 2020 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
(Am J Cardiol 2020;00:1−9)f Cardiology, Thoraxcenter, Erasmus University Medi-
dam, The Netherlands; bDepartment of Radiology and
, Erasmus University Medical Center, Rotterdam, The
cDepartment of Clinical Radiology, Kyushu University,
anuscript received November 25, 2019; revised manu-
accepted February 4, 2020.
uthors state that this work has not received any funding.
ibuted equally to this work.
g author: Tel: +31107040704.
s: a.hirsch@erasmusmc.nl (A. Hirsch).
www.ajconline.orgThe Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
ativecommons.org/licenses/by-nc-nd/4.0/)
1016/j.amjcard.2020.02.002Hypertrophic cardiomyopathy (HC) is the most common
inherited cardiac disease that affects at least 0.2% of the
general population.1 Although many patients diagnosed
with HC present without or with minimal physical symp-
toms, a substantial group will experience mild to severe
chest pain. The etiology of chest pain in HC patients is
complex and includes myocardial ischemia, an increased
metabolic demand and reduced myocardial blood supply.1-3
HC patients are not exempt from coronary artery disease
(CAD).1,4 HC patients with concomitant CAD are at a
higher risk of cardiac death compared with those without
coexistent CAD.4,5 Therefore, early diagnosis of CAD is
important in symptomatic HC patients. Coronary computed
tomography angiography (CCTA) is an excellent tool in the
evaluation of chest pain, particularly to rule out CAD,especially in patients with low-to-intermediate risk for
CAD.3,6 Another added benefit of CCTA is the assessment
of myocardial bridging (MB), which is reported to be par-
ticularly prevalent in HC.7-9 MB is generally benign, but a
relation with accelerated atherosclerosis, vasospasm, chest
pain, and sudden cardiac death has been described.10-12
Limited data exists on the value of CCTA in patients with
HC and chest pain in the context of MB and CAD. In this
study, we aimed to evaluate differences in the prevalence of
MB and CAD using CCTA between HC patients and a
group of age-, sex- and pre-test probability (PTP)-matched
outpatients presenting with chest pain.Methods
For this single-center retrospective observational study,
we screened patients enrolled in the Inherited Cardiomyopa-
thy registry of the Erasmus Medical Center, Rotterdam, the
Netherlands. We included those diagnosed with HC and who
underwent CCTA between September 2005 and May 2018
for chest pain, angina equivalent symptoms (e.g., exertional
dyspnea), or other indications. Chest pain was categorized
as typical angina, atypical angina, or nonanginal chest pain.
Typical angina was defined as (1) substernal chest discom-
fort of characteristic quality and duration, (2) provoked by
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2 The American Journal of Cardiology (www.ajconline.org)exertion or emotional stress, and (3) relieved by rest and/
or nitrates within minutes.6 Chest pain was considered
atypical or non-anginal if two, respectively one or none of
the above-mentioned characteristics were met. The diag-
nosis of HC was based on a maximal wall thickness
≥15 mm in probands or ≥13 mm in first-degree relatives,
not solely explained by loading conditions.1 Patients with
HC caused by Anderson-Fabry disease, Danon disease,
Noonan syndrome, amyloidosis, or other confirmed meta-
bolic or mitochondrial disorders or malformation syndromes
were excluded.
The control group consisted of adult patients with stable
chest pain or angina equivalent symptoms who were
referred to the Erasmus Medical Center for the evaluation
of CAD and underwent CCTA between September 2006
and March 2017. Patients were not eligible if they were
known to have left ventricular hypertrophy (LVH) or had
elektrocardiogram findings consistent with LVH to mini-
mize the possibility of including HC patients in the control
group, and were also excluded whenever CT scans were
incomplete (i.e., scans without contrast) or when image
quality was insufficient. Patients were matched by an opti-
mal matching algorithm in a 1:2 ratio on age (caliper dis-
tance § 5 years), gender and PTP for CAD (§3%), as
calculated using the CAD Consortium clinical risk
score.6,13 This is a validated risk score incorporating age,
gender, type of chest pain, and cardiac risk factors (diabe-
tes, hypertension, dyslipidemia, and past or current smok-
ing). The institutional review board approved this study.
Participants were not involved in the design and conduct of
the current research.
CCTA was performed on a 64-slice or more advanced CT
system (Somatom Definition or Definition Flash, Siemens
Healthineers) with radiation minimizing strategies, heartbeat,
and vasodilatation policies according to guidelines and local
protocols. All control patients were scanned in a fast-track
chest pain outpatient clinic setting, described previously.14
Assessment of image quality and analysis were performed
by one experienced radiologist (YY), using Syngo.via (Client
1.2, Siemens). Calcium scores were calculated using the
Agatston method.15 The extent of CAD was evaluated using
an 18-segment model as recommended by the Society of
Cardiovascular Computed Tomography.16 Stenosis severity
was classified per segment as 0%, <25%, 25% to 49%, 50%
to 69%, 70% to 99%, or a total occlusion (100%). Obstruc-
tive CAD was defined as the presence of ≥1 coronary vessel
with ≥50% lumen diameter reduction. Plaques were scored
on degree of calcification and divided in calcified, noncalci-
fied and mixed plaques. MB was defined as a segmental
intramyocardial course of any epicardial coronary artery,
only when fully enveloped by the myocardium without fur-
ther requirements for length and depth. Bridge dimensions
were measured using multiplanar reconstruction images.
Baseline was defined as the date of CCTA. Data were
collected from outpatient visit medical records and included
medical (family) history, physical examination, electrocardi-
ography, and transthoracic echocardiography. Hypertension
was defined as a blood pressure ≥140/90 mm Hg or treat-
ment with antihypertensive medication.17 Diabetes mellitus
was defined as a fasting glucose level of ≥7.0 mmol/L or the
need for insulin or oral hypoglycemic agents.18 Dyslipidemiawas defined as a total serum cholesterol level of≥5.2 mmol/L
or treatment with lipid-lowering medication. A positive fam-
ily history for cardiovascular disease was defined as a history
of CAD in first degree relatives less than 55 years in males
and less than 65 years in females.19
For the HC group, follow-up data were collected until
December 2018, which included all-cause mortality,
cardiac transplantation, aborted sudden cardiac death, and
heart failure. Aborted sudden cardiac death was defined as
resuscitation after cardiac arrest or appropriate implantable
cardioverter-defibrillator intervention. Heart failure was
defined as (1) the presence of clinical signs of congestion
(including dyspnea, fatigue, and edema) requiring the use of
diuretics in an outpatient setting, or (2) an episode of decom-
pensation requiring hospital admission. Acute myocardial
infarction and admissions for unstable angina were registered
but were not included in the combined end point due to the
absence of these events during follow-up. Clinical data was
retrieved from our hospital patient records and mortality data
was retrieved from civil service population registers.
Continuous data were tested for normality before analy-
sis using the Kolmogorov-Smirnov test and were expressed
as mean § standard deviation (SD) or median [interquartile
range], as appropriate. Categorical variables were pre-
sented as number (%). We compared baseline characteris-
tics and aspects of CAD between those with HC and their
matched controls. To account for matching of the data,
general and generalized linear mixed-effects models were
used for continuous and categorical dependent variables,
respectively, with random intercepts for pairs of matched
subjects. Case-control status was entered as the indepen-
dent variable. Subsequently, we compared characteristics
of HC patients according to presence or absence of MB.
Continuous variables were compared using Student’s t test
and categorical data were compared using Pearson’s x2
test. Kaplan-Meier survival analysis was performed to
estimate the cumulative survival for the combined end
point sudden cardiac death, cardiac transplantation, heart
failure, and all-cause mortality in HC patients with and
without MB. All analyses were 2-tailed; p values <0.05
were considered statistically significant. Statistical analy-
ses were performed using SPSS version 24 (IBM Corp.,
Armonk, New York) and R statistical software version
3.4.2, using packages nlme, lme4 and car.Results
A total of 84 patients diagnosed with HC and 168 age-,
sex- and PTP-matched control patients were included in
this study (Figure 1). Baseline patient characteristics of
both groups are summarized in Table 1. Overall, the mean
age was 54 § 11 years, 70% were male and the majority
had a low PTP score for CAD (12 [4 to 32]). The groups
were similar in respect to most demographic characteristics,
but differed regarding CT indications. Patients in the HC
group were less likely to undergo CCTA for nonanginal
chest pain, but more often underwent CCTA for other indi-
cations, including preintervention screening and exclusion
of ischemia for reasons other than symptoms, that is a
reduced ejection fraction or an akinetic apex on echocardi-
ography. b-blocker and calcium channel blocker usage was
Figure 1. Flowchart patient selection.
Abbreviations: CCTA = coronary computed tomography angiography; CMP = cardiomyopathy; EMC = Erasmus Medical Center; HC = hypertrophic cardio-
myopathy; PTP = pre-test probability score.
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aspirin and other antiplatelet agents at baseline was not sta-
tistically significant between the groups.
In the HC group, half of the patients were classified as
NYHA II and nearly half were known with a pathogenic
DNA variant. In 90% of HC patients left ventricular systolic
function was normal or mildly reduced, and over half had
stage I or II diastolic dysfunction. The median maximal wall
thickness was 17 [14 to 20], 14 patients had obstructive mor-
phology, and 10 had a history of septal reduction therapy.
Differences in CAD characteristics between cases and
controls are shown in Table 2. Groups were similar with
regard to calcium score, presence of obstructive CAD, pla-
que morphology, and extent of disease. MB was far more
prevalent in the HC group compared with controls, both on
the group-level and individually, with MB present in 50%
of HC patients compared with 25% of controls and with a
larger proportion of HC patients having multiple bridges.
There was a predilection for MB in the mid-left anterior
descending artery in both groups. Typically, the length and
depth of MB was higher in the HC group, although this did
not reach statistical significance. Also, no relationship was
found between maximal wall thickness and depth and/or
length of MB in both groups. Examples of MB on CCTA
are shown in Figure 2.
HC patients were stratified according to the presence or
absence of MB (Table 3). HC patients with and without
MB were similar in regard to demographic factors, cardiac
risk profile, and HC disease severity according to NYHA
classification and echocardiographic parameters. However,pathogenic DNA variations were more prevalent in patients
with MB compared with patients without MB. Chest pain
was equally prevalent in both groups, and there were no dif-
ferences regarding chest pain characteristics. Also, the pres-
ence of CAD was lower in HC patients with MB. This
difference was also seen when comparing patients with and
without MB in the entire cohort (obstructive CAD: 23% vs
10%, all CAD: 58% vs 42%; p <0.05 for both), but not in
the control subgroup only (obstructive CAD: 23% vs 10%;
p = 0.36; all CAD: 58% vs 42%; p = 0.21).
During a median follow-up of 3.7 [1.8 to 6.1] years a
total of 25 cardiac events ([aborted] sudden cardiac death,
cardiac transplantation, heart failure, and all-cause mortality)
occurred, 14 in the MB group and 11 in the group without
MB. There was no significant difference in event-free sur-
vival for the composite end point between both groups (log-
rank p = 0.30; Figure 3). Also, no significant difference in
event-free survival was found in HC patients with and with-
out obstructive CAD (log-rank p = 0.25, Figure S1). No myo-
cardial infarction or admissions for unstable angina occurred
during follow-up. A total of 12 HC patients underwent coro-
nary arterial revascularization (percutaneous coronary inter-
vention, n = 10, or coronary artery bypass grafting, n = 2),
9 of which were performed following baseline CCTA results
and 3 after a follow-up of 2, 7, and 11 years. MB was present
in 25% of treated patients.
In a sensitivity analysis including only the 52 HC patients
who underwent CCTA for chest pain and their matched con-
trols, the results were comparable to the presented data
including the whole cohort (data not shown).
Table 1
Baseline characteristics
Variable HC (n = 84) Controls (n = 168) p value
Age (years) 54 § 11 54 § 10 0.96
Men 59 (70%) 118 (70%) 1.0
Body mass index
(kg/m2)
26.8 § 4.0 26.8 § 4.7 0.96
Pre-test probability
score
13.5 [4.7 − 29.8] 11.8 [4.3 − 32.0] 0.88
Indication for CCTA
Chest pain
Typical 20 (24%) 46 (27%) 0.54
Atypical 26 (31%) 67 (40%) 0.17
Non-specific 6 (7%) 42 (25%) 0.001
No chest pain 32 (38%) 13 (8%) <0.001
Pre-surgery 10 (12%)
Pre-ablation 9 (11%)
Other 13 (15%)
Hypertension 31 (37%) 67 (40%) 0.65
Dyslipidemia 30 (36%) 57 (34%) 0.79
Diabetes mellitus 9 (11%) 16 (10%) 0.78
Smoker
Current 21 (25%) 40 (24%) 0.84
Past 25 (30%) 17 (10%) <0.001
HC characteristics
NYHA class
I 35 (42%)
II 42 (50%)
III 7 (8%)
Pathogenic DNA
variant
39 (46%)
Cardiac device
PM 3 (4%)
ICD 11 (13%)
Septal reduction
therapy
10 (12%)
Maximal wall
thickness (mm)
17 [14 − 20]
Peak LVOT gradient
(mm Hg)
6 [4 − 8]
Presence of LVOT
obstruction
(peak gradient
≥30 mm Hg)
14 (17%)
Left atrial diameter
(mm)
45 [39 − 49]
Presence of systolic
anterior movement
21 (25%)
LV ejection fraction*
>51% 59 (72%)
41% - 51% 17 (21%)
30% - 40% 4 (5%)
<30% 2 (2%)
LV diastolic function**
Normal 13 (16%)
Stage I 18 (23%)
Stage II 40 (51%)
Stage III 8 (10%)
Medications
ß-blocker 48 (57%) 51 (31%) <0.001
Calcium channel
blockers
23 (27%) 24 (14%) 0.01
Diuretics 23 (27%) 21 (13%) <0.01
Statins 28 (33%) 68 (41%) 0.27
(continued)
Table 1 (Continued)
Variable HC (n = 84) Controls (n = 168) p value
ACE inhibitors 17 (20%) 23 (14%) 0.20
Aspirin 20 (24%) 53 (32%) 0.19
Antiplatelet agents 1 (1%) 11 (6%) 0.08
*Data available in 82 patients.
**Data available in 79 patients.
Abbreviations: ACE = angiotensin converting enzyme; CCTA = coro-
nary computed tomography angiography; HC = hypertrophic cardiomyop-
athy; ICD = implantable cardioverter-defibrillator; LV = left ventricle;
LVOT = left ventricle outflow tract obstruction; NYHA =New York Heart
Association; PM = pacemaker. Data presented as mean +/ SD, median
with IQR or n (%).
p values are from mixed models.
Table 2
Assessment of coronary artery disease by cardiac Coronary Computed
Tomography Angiography
Variable HC (n = 84) Controls
(n = 168)
p value
Patient based analysis
Coronary artery disease
Agatston score* 9 [0 − 225] 4 [0 − 82] 0.22
No. of patients with score* 0.07
0 31 (43%) 77 (47%)
1 − 99 16 (22%) 52 (32%)
100 − 399 18 (25%) 20 (12%)
>400 8 (11%) 15 (9%)
Obstructive CAD 15 (18%) 32 (19%) 0.82
Artery affected 0.80
1 10 (12%) 17 (10%)
2 3 (4%) 10 (6%)
3/left main 2 (2%) 5 (3%)
Only non-calcified plaques 13 (15%) 31 (18%) 0.56
Myocardial bridging
No. of patients with MB 42 (50%) 42 (25%) <0.001
No. of arteries with MB <0.001
1 34 (40%) 39 (23%)
2 8 (10%) 3 (2%)
No. of pts. with >1 MB segments 12 (14%) 4 (2%) <0.001
Per segment
Location of MB
Left anterior descending
Proximal 0 0 n/a
Mid 34 (40%) 30 (18%) <0.001
Distal 9 (11%) 2 (1%) 0.001
Diagonal 2 (2%) 3 (2%) 1.0
Left circumflex
Proximal 0 0 n/a
Distal 0 0 n/a
Obtuse marginal 6 (7%) 5 (3%) 0.19
Intermediate branch 5 (6%) 6 (4%) 0.51
Right coronary 1 (1%) 0 0.33
Dimensions of MB (length and depth in mm)
Left anterior descending 21 § 14
2 § 2
17 § 8
2 § 1
0.18
0.47
Left circumflex 24 § 14
2 § 1
28 § 12
2 § 1
0.51
0.42
Right coronary 20
1
-
-
-
-
*Data missing in 11 HC patients and in 4 control patients respectively.
Abbreviations: CAD = coronary artery disease; MB =myocardial
bridging.
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Figure 2. Examples of myocardial bridging on cardiac Coronary Computed Tomography Angiography in HC patients.
Multiplanar reformats in 2 representative HC patients.
Patient 1 (A-C): Respectively 4 chamber, modified 2 chamber and short axis view showing myocardial bridging of the left anterior descending artery (white
arrow). Asterix indicates ICD lead.
Patient 2 (D-F): Respectively 4 chamber and short axis view and 3D reconstruction showing myocardial bridging of the left anterior descending artery (white
arrow).
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In this study, we evaluated the prevalence of MB and
CAD in HC patients and compared these results with age-,
gender- and CAD PTP-matched outpatients presenting
with chest pain. The main findings are that the prevalence
of obstructive CAD was comparable and that MB was
present in 50% of HC patients, twice as much as in con-
trols. The location of MB was predominantly in the (mid)
left anterior descending artery, with only a minority of
bridging in other vessels. HC patients with MB were more
likely to have pathogenic DNA variants and less likely to
have (obstructive) CAD, but did not differ regarding the
presence of chest pain or worse outcome compared with
those without MB.
The prevalence of obstructive CAD in our study was
19%, which is similar to other cohorts with low or inter-
mediate PTP.4,5 Concomitant CAD in HC is associated
with decreased survival, demonstrating the importance of
a prompt, and accurate diagnostic work-up. In HC patients
presenting with chest pain, this work-up is similar to non-
HC patients. Common abnormalities on resting electrocar-
diograms and the reduced discriminatory power of nuclear
imaging and cardiovascular magnetic resonance imaging
with regard to causes of perfusion defects imply a high
likelihood of false-positive results, limiting the use of these
modalities in differentiating CAD from other causes of chest
pain.1 Moreover, as the etiological spectrum of chest pain inHC patients is wider than in the general population, use of
prediction models for CAD could theoretically overestimate
the true presence of CAD in this patient group. However, our
data illustrate that, using a 1:2 matched analysis, both abso-
lute calcium scores as well as the presence of obstructive
CAD are similar across groups. Previous research has shown
that CCTA is an excellent modality particularly for ruling
out CAD in HC patients.20,21 This combined with the nonin-
vasive and generally safe nature of this modality, demon-
strates that CCTA is a useful modality for the evaluation of
chest pain in HC.
Several other studies have investigated the prevalence of
CAD in HC, with rates ranging from 6.6% to 26%.4,8,22 The
differing rates are most likely explained by differences in
age and patient selection, with a 13% presence of CAD in
an autopsy study done on 115 HC patients with a median
age of 29 and a 26% prevalence of CAD in 433 HC patients
with a median age of 63 who were referred for invasive cor-
onary angiography. However, in a case-control study evalu-
ating CCTA done by Shiarat et al. in 91 HC patients and
91 controls, rates of CAD were remarkably lower in HC
patients (6.6%) and higher in controls (33%). It is possible
that more elaborate matching on risk score mitigates the
observed difference in their study, although prevalence of
risk factors was comparable among their study groups.
Other potentially relevant factors are differences in gender
distribution (70% males in our population vs 54% males in
the population of Shiarat et al.) and chest pain type. As
Table 3
Patient characteristics of HC patients stratified according the presence or
absence of myocardial bridging
Variable Bridging
(n = 42)
No bridging
(n = 42)
p value
Age (years) 54 § 11 55 § 12 0.55
Men 28 (67%) 31 (74%) 0.47
Body mass index (kg/m2) 27.1 § 4.1 26.4 § 3.6 0.39
Median pre-test probability 14.1 [4.8 − 29.1] 12.1 [4.5 − 33.6] 0.83
Hypertension 15 (36%) 16 (38%) 0.82
Dyslipidemia 17 (40%) 13 (31%) 0.36
Diabetes mellitus 5 (12%) 4 (10%) 0.72
Smoker
Current 10 (24%) 11 (26%) 0.80
Past 12 (29%) 13 (31%) 0.81
NYHA class 0.86
I 17 (41%) 18 (43%)
II 22 (52%) 20 (48%)
III 3 (7%) 4 (10%)
Symptoms
Chest pain 31 (74%) 32 (76%) 0.80
Dyspnea 20 (48%) 23 (55%) 0.51
Palpitations 15 (36%) 13 (31%) 0.64
Syncope 6 (14%) 4 (10%) 0.50
Genetics
Patient genetically tested 37 (88%) 38 (91%) 0.72
Pathogenic DNA variant
(% of whole group)
26 (62%) 17 (41%) 0.049
Pathogenic DNA variant
(% of tested group)
26 (70%) 17 (45%) 0.03
MYBPC3 16 (43%) 10 (26%) 0.12
MYH7 5 (14%) 1 (3%) 0.08
Other 5 (14%) 6 (16%) 0.78
CCTA 0.71
Indications
Chest pain 0.80
Typical 13 (31%) 13 (31%)
Atypical 11 (26%) 9 (21%)
Non-anginal 4 (10%) 2 (5%)
No chest pain 14 (33%) 18 (41%)
Agatston score* 0 [0 − 88] 44 [0 − 320] 0.02
Presence of CAD 16 (38%) 26 (62%) 0.03
Obstructive CAD 2 (5%) 13 (31%) <0.01
HC characteristics
Cardiac device
PM 2 (5%) 1 (2%) 0.56
ICD 6 (14%) 5 (12%) 0.75
Septal reduction therapy 5 (12%) 5 (12%) 1.0
Maximal wall thickness (mm) 18 § 6 17 § 4 0.17
Peak LVOT gradient (mmHg) 6 [4 − 8] 6 [4 − 12] 0.18
Presence of obstruction 5 (12%) 9 (22%) 0.24
Left atrium diameter (mm) 43 [39 − 49] 46 [40 − 49] 0.4
Presence of systolic
anterior movement
8 (20%) 13 (32%) 0.21
LV ejection fractiony 0.10
>51% 28 (68%) 31 (76%)
41% - 51% 9 (22%) 8 (20%)
30% - 40% 4 (10%) 0
<30% 0 2 (5%)
LV diastolic functionz 0.40
Normal 6 (16%) 7 (17%)
Stage I 7 (18%) 11 (27%)
Stage II 19 (50%) 21 (51%)
Stage III 6 (16%) 2 (5%)
(continued)
Table 3 (Continued)
Variable Bridging
(n = 42)
No bridging
(n = 42)
p value
Medications
ß-blocker 26 (62%) 22 (52%) 0.38
Calcium channel blockers 8 (19%) 15 (36%) 0.09
Diuretics 14 (33%) 9 (21%) 0.22
Statins 15 (36%) 13 (31%) 0.64
ACE inhibitors 9 (21%) 8 (19%) 0.79
Aspirin 10 (24%) 10 (24%) 1.00
Antiplatelet agents 1 (2%) 0 0.32
Other pathogenic DNA variants include TNNI3 (2 vs 2), ALPK3 (1 vs 1),
MYL2 (1 vs 1),MYL3 (0 vs 1), PKP2 (0 vs 1), FHL1 (1 vs 0).
Abbreviations: ACE = angiotensin converting enzyme; CAD = coronary
artery disease; CCTA = coronary computed tomography angiography;
HC = hypertrophic cardiomyopathy; ICD = implantable cardioverter-defi-
brillator; LV = left ventricle; LVOT = left ventricular outflow tract;
NYHA =New York Heart Association; PM = pacemaker.
*Data available in 39 patients with MB and 35 without MB.
yData available in 41 patients of both groups.
zData available in 38 patients with MB and in 41 patients without MB.
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cannot readily draw conclusions on this.
The prevalence of MB ranges in the literature ranges
from 1% to 86% and varies according to the method of
evaluation, the definition of bridging, and the population of
interest. The highest rates are generally reported in autopsy
studies and lower rates are seen in studies involving CCTA
and invasive coronary angiography.7,22,23 The presence of
MB in HC cohorts is higher than in the general population,
with reported rates of up to 41%.7,8 In concordance with the
literature, our study shows a prevalence of MB of 50%
in HC patients, compared with 25% in controls. The most
commonly affected coronary segment was the mid-left
descending artery, which seems to be consistent across
most studies.7 The different rates seen in CCTA and inva-
sive coronary angiography studies can be explained by the
properties of both methods and the physiological properties
of MB. Higher detection rates of MB are expected with
CCTA due to its capability to show the anatomical course
of the coronary arteries with quantification of length and
depth of MB.5 Invasive coronary angiography generally
relies on the presence of systolic compression of the
affected segment (i.e., the milking effect), which makes it
more likely for smaller or noncompressing MBs to not be
recognized.7 Detection of MB may be relevant to explain
the cause of chest pain, but currently no scientifically
proven therapy is available. Symptomatic patients can be
treated with negative chronotropic drugs, which would
lessen the burden of MB by prolonging the diastolic
phase.24 In our study, chest pain characteristics as well as
its overall prevalence did not differ among HC patients
with and without MB. Interestingly, Kawai et al. recently
illustrated the association of MB with coronary vasospasm,
a well-known etiological substrate of chest pain which
offers another explanation as to how MB can cause chest
pain.25 However, the current study suggests the lack of an
association between MB and chest pain, and despite
the high prevalence of MB in this HC cohort, the clinical
relevance of this finding seems limited at best.
Figure 3. Kaplan-Meier estimates of the combined end point aborted sudden cardiac death, cardiac transplantation, heart failure and all-cause mortality in
hypertrophic cardiomyopathy patients with and without myocardial bridging.
CCTA = coronary computed tomography angiography.
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a significant association was found between MB and the
presence of pathogenic DNA variations. The mechanism
behind the increased prevalence of MB in HC has, to our
knowledge, not been elucidated yet. Although MB is often
considered to be a congenital anomaly, there are reports
suggesting that MB can be an acquired, particularly in the
context of LVH.26,27 However, our study showed no rela-
tionship between the severity of MB and maximal wall
thickness of the left ventricle. Adding to previously
reported literature, we did not find evidence for worse
prognosis in our relatively small population of HC patients
with MB.28,29
This study has several limitations. First, this study is
sensitive for recall bias due to its retrospective design.
Secondly, selection bias was present as CCTA was per-
formed in a small population of HC patients with chest
pain. We aimed to overcome these limitations by employ-
ing a matched case-control design and by taking into
account the paired nature of the data in our analysis. Fur-
thermore, we acknowledge that our analyses are prone to
type II errors owing to the relatively small sample size of
our study. Additionally, as the clinical impact of MB in
HC patients has, to our knowledge, only been demon-
strated in children, it is possible that our survival analysis
is influenced by a survival bias.20,21 By excluding known
LVH in the control group, it is possible that the incidence
of MB is underestimated. Lastly, no follow-up data was
available in the control group.
In conclusion, the prevalence and extent of CAD was
equal among patients with and without HC, demonstrating
that pre-test risk prediction using the CAD Consortium
clinical risk score performs well in HC patients. MB was
twice as prevalent in the HC group compared to matched
controls, but was not associated with chest pain or
decreased event-free survival in these patients.Author Contribution Section
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